OSCR
New baton pass from Wall Street
Oscar Health got a fresh vote of confidence from Raymond James, which upgraded the insurer to Outperform from Market Perform and set an $18 price target. Not exactly a confetti cannon, but in analyst-land that’s a pretty friendly nudge.
Why the bull case is getting louder
The firm’s pitch is basically: Oscar’s valuation looks attractive, and the company’s margins are starting to recover across the Affordable Care Act exchange market. In plain English, Wall Street is betting the business is getting better at turning all that membership growth into something more profitable than a nice-looking spreadsheet.
The messy part is still messy
Oscar’s recent Q4 miss is still hanging around like a bad group text, but Raymond James called it backward-looking. The bigger story, they argued, is the forward view — and that outlook sounds a lot sturdier than the rear-view mirror version.
Why you should care
Oscar says it now has 3.4 million members after the 2026 enrollment period, up from 2 million at the end of 2025. That’s a huge jump, but the industry is still dealing with rising healthcare costs and ACA subsidy uncertainty, so this isn’t some victory lap on a float parade.
Big picture: if Oscar can keep growing membership without letting costs eat the whole lunch, the market may stop treating OSCR like a risky side quest and start pricing it more like a real operating business.